HSBC upgraded Iqvia (IQV) to Buy from Hold with a price target of $235, up from $195. The firm expects easing regulatory “clouds” in pharma to support a re-rating of the shares. Iqvia’s Q3 commentary on book-to-bill and requests for proposal flows will be catalysts for the shares, the analyst tells investors in a research note. HSBC views the company as a “geared play in a recovery cycle” and sees attractive risk/reward into the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target raised to $240 from $220 at Evercore ISI
- Iqvia price target raised to $200 from $185 at Barclays
- Early notable gainers among liquid option names on October 1st
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Lululemon downgraded, Dick’s Sporting upgraded: Wall Street’s top analyst calls